Post‐chemotherapy ypT1‐2ypN1 BC patients might have worse initial clinical TN stages or pathologic responses compared to de novo pT1‐2N1 BC patients, but we found no significant prognostic differences in these two populations, possibly because of the better prognosis of post‐chemotherapy BC patients with new NAC regimens such as adriamycin and taxol in modern treatment modalities. Here, RAB1A is linked to breast cancer.